“Revamping for Success: BriaCell Consolidates Shares for a Brighter Future”
BriaCell Therapeutics Completes Share Consolidation Philadelphia and Vancouver – January 27, 2025 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT), a clinical-stage biotechnology company focusing on developing novel immunotherapies for cancer treatment, announced on January 24, 2025, that they have completed a share consolidation. The consolidation involved combining every fifteen pre-consolidation common shares into one…